With the finding that SGLT2 is expressed in many different tumors, SGLT2i shows great potential for tumor treatment; a large number of in vitro studies have shown that SGLT2i can inhibit tumor growth and improve prognosis through multiple pathways independent of glucose-lowering effects, as well as reduce the side-effects of chemotherapeutic drugs and enhance the sensitivity, so there is a great potential for the application of SGLT2i. The gene discussed is SLC5A2; the disease is neoplasm.